Cardiff Oncology, Inc. (CRDF) compared with its closest peers (PROK, KLRS, ATRA, CGTX, OTLK). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| ProKidney Corp. (PROK) | $99.70M | -29.8 |
| Kalaris Therapeutics Inc (KLRS) | $98.79M | -2.9 |
| Atara Biotherapeutics, Inc. (ATRA) | $98.07M | 7.0 |
| Cognition Therapeutics, Inc. (CGTX) | $95.07M | -4.2 |
| Outlook Therapeutics, Inc. (OTLK) | $78.25M | — |
| Champions Oncology, Inc. (CSBR) | $70.30M | 17.6 |
| INmune Bio, Inc. (INMB) | $63.83M | -0.8 |
| ImageneBio Inc (IMA) | $63.34M | -0.7 |
| MiNK Therapeutics, Inc. (INKT) | $62.21M | -3.8 |
| Scilex Holding Company (SCLX) | $48.07M | -0.3 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
CRDF overview · CRDF earnings · CRDF financials · CRDF KPIs · CRDF investor relations · CRDF ownership · CRDF filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.